Elsevier

Survey of Ophthalmology

Volume 42, Issue 2, September–October 1997, Pages 99-123
Survey of Ophthalmology

Major review
Current concepts in giant cell (temporal) arteritis

https://doi.org/10.1016/S0039-6257(97)00052-0Get rights and content

Abstract

Giant cell (temporal) arteritis continues to be a sight-threatening, systemic vasculitis with a poorly understood pathogenesis. The characteristic granulomatous inflammation of the vessel wall commonly leads to local ischemia. Recent advances in immunological investigations have characterized the cellular components of the disease process, but the etiology has so far remained unresolved. A reappraisal of the clinical features of giant cell (temporal) arteritis demonstrates the heterogeneity of the manifestations of the disease, including ischemic optic neuropathy. A range of new laboratory investigations and blood flow studies with color Doppler imaging have demonstrated promising roles, with respect to diagnosis and long-term follow-up. Prompt diagnosis and expeditious treatment require a high index of clinical suspicion, particularly for atypical cases. Corticosteroids remain the treatment of choice, other immuno-suppressive agents being used as second line steroid-sparing agents. Giant cell (temporal) arteritis leads to increased vascular and visual morbidity and, if untreated, may prove fatal. To maintain high standards of management of this enigmatic disorder, ophthalmologists need to be aware of the clinical spectrum of giant cell (temporal) arteritis and currently available diagnostic tests and treatment strategies.

References (349)

  • P Berlit

    Clinical and laboratory findings with giant cell arteritis

    J Neurol Sci

    (1992)
  • DC Bienfang

    Use of the Doppler probe to detect the course of the superficial temporal artery

    Am J Ophthalmol

    (1984)
  • FX Borruat et al.

    Orbital infarction syndrome

    Ophthalmology

    (1993)
  • R.J. Caselli et al.

    Neurologic aspects of giant cell (temporal) arteritis

    Rheum Dis Clin North Am

    (1993)
  • J Chess et al.

    Serologic and immunopathologic findings in temporal arteritis

    Am J Ophthalmol

    (1983)
  • J.F. Cullen et al.

    Ophthalmic complications of giant cell arteritis

    Surv Ophthalmol

    (1976)
  • R.H. Davis et al.

    Tonic pupil after temporal arteritis

    Lancet

    (1968)
  • KN Achar et al.

    Biliary ultrastructural changes in the liver in a case of giant cell arteritis

    Br J Rheumatol

    (1994)
  • A.A. Achkar et al.

    Giant cell arteritis involving the facial artery

    J Rheumatol

    (1995)
  • A.A. Achkar et al.

    How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?

    Ann Intern Med

    (1994)
  • DM Albert et al.

    Skip areas in temporal arteritis

    Arch Ophthalmol

    (1976)
  • MC Allison et al.

    Temporal artery biopsy and corticosteroid treatment

    Ann Rheum Dis

    (1984)
  • C.J. Allsop et al.

    Temporal artery biopsy in giant cell arteritis. A reappraisal

    Am J Surg Pathol

    (1981)
  • P Amalric

    Acute choroidal ischemia

    Trans Ophthalmol Soc UK

    (1974)
  • R Andersson et al.

    HLA-DR expression in the vascular lesion and circulating T lymphocytes of patients with giant cell arteritis

    Clin Exp Immunol

    (1988)
  • R Andersson et al.

    T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis

    Ann Rheum Dis

    (1987)
  • R Andersson et al.

    Long-term corticosteroid treatment in giant cell arteritis

    Acta Med Scand

    (1986)
  • R Andersson et al.

    Long-term survival in giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study of 90 patients treated with corticosteroids

    Acta Med Scand

    (1986)
  • R Andersson et al.

    Acute phase reactants in the initial phase of giant cell arteritis

    Acta Med Scand

    (1986)
  • R.D. Armstrong et al.

    Histocompatibility antigens in polymyalgia rheumatica and giant cell arteritis

    J Rheumatol

    (1983)
  • MH Arnold et al.

    The sensitivity and specificity of reduced CD8 lymphocyte levels in the diagnosis of polymyalgia rheumatica/giant cell arteritis

    Clin Exp Rheumatol

    (1993)
  • A Askari et al.

    Internuclear ophthalmoplegia and Horner's syndrome due to presumed giant cell arteritis

    J R Soc Med

    (1993)
  • J Astrup et al.

    Thresholds in cerebral ischemia—the ischemic penumbra

    Stroke

    (1981)
  • O Baldursson et al.

    Giant cell arteritis in Iceland. An epidemiologic and histopathologic analysis

    Arthritis Rheum

    (1994)
  • PM Banks et al.

    Immunohistologic and cytochemical studies of temporal arteritis

    Arthritis Rheum

    (1983)
  • TA Baranger et al.

    Absence of antineutrophil cytoplasmic antibodies in giant cell arteritis

    J Rheumatol

    (1994)
  • M.E. Barricks et al.

    Ophthalmoplegia in cranial arteritis

    Brain

    (1977)
  • J Barrier et al.

    The use of Doppler flow studies in the diagnosis of giant cell arteritis. Selection of temporal artery biopsy site is facilitated

    JAMA

    (1982)
  • TAG Bell et al.

    A case of giant-cell arteritis and Horner's syndrome

    Scott Med J

    (1980)
  • B.A. Bengtsson et al.

    An alternate-day corticosteroid regimen in maintenance therapy of giant cell arteritis

    Acta Med Scand

    (1981)
  • B.A. Bengtsson et al.

    The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications

    Arthritis Rheum

    (1981)
  • B.A. Bengtsson et al.

    Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids

    Acta Med Scand

    (1981)
  • C Benlahrache et al.

    Decrease of the OKT8 positive T cell subset in polymyalgia rheumatica. Lack of correlation with disease activity

    Arthritis Rheum

    (1983)
  • G Bennett

    Cortisone therapy of visual loss in temporal arteritis

    Br J Ophthalmol

    (1956)
  • A.L. Bergstrom et al.

    Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy

    Ann Rheum Dis

    (1979)
  • H Bettelheim

    Differential diagnosis of ocular ischemia by ophthalmodynamography

    Trends Ophthalmol Soc UK

    (1971)
  • NC Birkhead et al.

    Treatment of temporal arteritis with adrenal corticosteroids: results in fifty five cases in which lesion was proved at biopsy

    JAMA

    (1957)
  • CM Birt et al.

    Anterior segment ischemia in giant cell arteritis

    Can J Ophthalmol

    (1994)
  • C Bisgard et al.

    Excess mortality in giant cell arteritis

    J Intern Med

    (1991)
  • DR Blake et al.

    Endothelial cell cytotoxicity in inflammatory vascular diseases—the possible role of oxidised lipoproteins

    Ann Rheum Dis

    (1985)
  • Cited by (81)

    • Characterization of serological markers of healed/healing arteritis and giant cell arteritis

      2018, Canadian Journal of Ophthalmology
      Citation Excerpt :

      Therefore, HH injury on TAB may represent active GCA, an inactive disease state that may not need to be aggressively treated, or a disease state that requires no treatment. Given this diagnostic equipoise, this TAB finding in case of high clinical suspicion is often treated with high-dose oral steroids in light of the potentially devastating consequences of delayed intervention, including blindness, aortitis, and stroke.1,8 Given that seromarker elevations in HH represent an intermediate state between GCA positive and GCA negative, this TAB finding likely represents a point on the continuum of the vasculitic process, from active to healed.

    • Visual Loss: Optic Neuropathies

      2018, Liu, Volpe, and Galetta's Neuro-Ophthalmology: Diagnosis and Management
    • New developments in giant cell arteritis

      2016, Survey of Ophthalmology
    • Giant cell arteritis

      2009, Journal of Clinical Neuroscience
      Citation Excerpt :

      Ischemia of extraocular muscles, ocular motor nerves or the brainstem may be responsible for diplopia and ocular motor imbalance, transient or constant, in 2% to 15% of GCA patients. The occulomotor (III) nerve is thought to be most commonly involved, often sparing the pupil; however, involvement of the trochlear (IV) and abducens (VI) nerves has been reported.30,45 While the exact etiology of GCA is unknown, a variety of infectious agents have been suggested as potential immune triggers for the disease, including herpes virus, parainfluenza virus, cytomegalovirus, parvovirus B19, chlamydia and mycoplasma.46–49

    View all citing articles on Scopus
    View full text